Abstract
Visual (VEP) and brainstem auditory (BAEP) evoked potentials (EP) were recorded in 21 multiple sclerosis (MS) patients in acute relapse before and after steroid treatment. VEPs were abnormal in 14/21 patients and BAEPs in 10/21 patients before treatment. In 4 patients with acute optic neuritis (ON), an improvement of VEPs paralleled clinical evolution in 3 cases. Substantial and contrasting changes in VEPs or BAEPs, with no clinical counterpart, were related to a spontaneous fluctuation of EPs in acute relapses of MS. These changes suggest frequent subclinical (multifocal and, possibly, sequential) central nervous system involvement in MS bouts. Group analysis showed nonsignificant changes in EP parameters before and after treatment. Our results indicate that evoked potentials (EPs) are of limited value for monitoring the short-term effect of steroid treatment in MS in bouts.
Sommario
I potenziali evocati visivi (VEP) ed acustici troncoencefalici (BAEP) sono stati eseguiti in 21 pazienti affentti da sclerosi multipla (SM) in fase di poussée, prima e dopo un ciclo di trattamento con steroidi. Prima del trattamento i VEP edi BAEP sono risultati alterati in 14 e 10 pazienti rispettivamente. 4 pazienti presentavano una neurite ottica (ON) in fase acuta; in 3, dopo il trattamento, è stato rilevato un significativo miglioramento dei VEP e dell'acuità visiva. Significative, ma contrastanti, modificazioni dei VEP e BAEP, riscontrate in altri 5 pazienti, non correlate all'evoluzione clinica, sono suggestive di un interessamento subclinico, multifocale e possibilmente sequenziale, durante una poussée della SM. L'analisi per gruppi non evidenzia differenze statistiche significative tra prima e dopo il trattamento. I nostri risultati indicano che i potenziali evocati sono di limitata utilità ai fini di un monitoraggio a breve termine della SM in poussée.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aminoff M.J., Davis S.L., Panitch H.S.:Serial evoked potential studies in patients with definite multiple sclerosis: clinical relevance. Arch. Neurol. 41:1197–1202, 1984.
Anderson D.C., Slater G.E., Sherman, R., Ettinger M.G.:Evoked potentials to test a treatment of chronic multiple sclerosis. Arch. Neurol. 44:1232–1236, 1987.
Bodis-Wollner I., Onofrj M.:System disease and visual evoked potentials diagnosis in neurology: changes due to synaptic malfunction. Ann. NY Acad. Sci. 388:327–348, 1982.
Confavreaux C;,Mauguière F., Courjon J.:Course of visual evoked potentials in multiple sclerosis: electrophysiological correlations and pathophysiological consideration in 25 patients. In: Courjon J: Mauguière F; Reval M (eds). Clinical application of evoked potentials in neurology. Raven Press, N.Y. pp 541–550, 1982.
Davis L.D., Aminoff M.J., Panitch H.S.:Clinical correlations of serial somatosensory evoked potentials in multiple sclerosis. Neurology 35:359–365, 1985.
Dieder H.C., Scheibler H.:Follow-up studies of visual potentials in multiple sclerosis evoked by checkerboard and foveal stimulation. Electroencephal. Clin. Neurophysiol. 49:490–496, 1980.
Ebers G.C., Vinuela F.V., Feasby T., Bass B.:Multifocal CT enhancement in multiple sclerosis. Neurology 34:341–346, 1984.
Fischer C., Maugurière F., Ibanez V., Courjon V.:Potentiels évoqués visuels, auditifs précoces et somesthésiques dans la scléroses en plaques (917 cas). Rev. Neurol. 142:517–523, 1986.
Fauci A.S.:Mechanisms of corticosteroid action on lymphocyte subpopulations. II-differential effects of in vivo hydrocortisone, prednisone and dexametazone on in vitro expression of lymphocyte functions. Clin Exp. Immunol. 24:54–62, 1976.
Mattehws W.B., Wattam-Bell J.R.B., Poutney E.:Evoked potentials in the diagnosis of multiple sclerosis: a follow-up study. J. Neurol. Neurosurg. Psy. 45:303–307 1982.
Matthewes W.B., Small D.G.:Serial recording of visual and somatosensory evoked potentials in multiple sclerosis. J. Neurol. Sci 40:11–21, 1979.
Milanese C., LaMantia L., Salmaggi A., Campi A., Eoli M., Scaioli V., Nespolo A., Corridori F.:Double-blind randomized trial of ACTH versus dexametazone versus methylprednisolone in MS in bouts. Clinical, CSF and neurophysiological results. Eur. Neurol. 29:10–14, 1989.
Nuwer M.R., Packwood I.M., Myers L.W., Ellison G.W.:Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 37:1754–1761, 1987.
Onofrj M., Basciani G., Censoni A.G., Gambi D.:Serial recording of VEPs to different stimuli in multiple sclerosis patients. It. J. Neurol. Sci. 113–119, 1986.
Smith T., Zeeberg I., Sjo O.:Evoked potentials in multiple sclerosis before and after high dose methylprednisolone infusion. Eur. Neurol 25:67–73, 1986.
Trojano R., Hafstein M., Rudermann M., Dowling P., Coo K.S.:Effect of high-dose i.v. steroid administration on contrast enhancing computed tomographic scan lesions in multiple sclerosis.Ann. Neurol. 15:257–264,1984.
Walsh J.C. Gerrick R., Cameron J., McLeod J.G.:Evoked potentials changes in clinically definite multiple sclerosis: a two year follow-up study. J. Neurol. Neurosurg. Psych. 45:494–500, 1982.
Yarom Y., Naparstek Y., Lev-Ram V., Holoshitz J., Ben-Nun A.,Cohen I.R.:Immunospecific inhibition of nerve conduction by T-lymphocytes reactive to basic protein of myelin. Nature 303:246–247, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scaioli, V., Milanese, C., Salmaggi, A. et al. Short term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment. Ital J Neuro Sci 13, 107–112 (1992). https://doi.org/10.1007/BF02226957
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02226957